Holen Sie sich die Stockscreener-App
7.50
4.31%
0.31
Schlusskurs vom Vortag:
$7.19
Offen:
$7.19
24-Stunden-Volumen:
382.68K
Relative Volume:
1.24
Marktkapitalisierung:
$502.32M
Einnahmen:
$555.06M
Nettoeinkommen (Verlust:
$-39.48M
KGV:
-12.50
EPS:
-0.6
Netto-Cashflow:
$29.05M
1W Leistung:
-0.92%
1M Leistung:
+0.13%
6M Leistung:
+9.33%
1J Leistung:
-34.33%
1-Tages-Spanne:
$7.19
$7.5143
1-Wochen-Bereich:
$7.015
$7.725
52-Wochen-Spanne:
$5.81
$11.75
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Vergleichen Sie BVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.50 | 481.56M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
122.55 | 210.84B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.70 | 137.17B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.80 | 133.55B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.77 | 127.71B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.92 | 48.33B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Bioventus (NYSE:BVS) Director Sells $75,700.00 in Stock - MarketBeat
Divisadero Street Capital Management LP Decreases Stock Position in Bioventus Inc. $BVS - MarketBeat
Geode Capital Management LLC Has $6.98 Million Stake in Bioventus Inc. $BVS - Defense World
American Century Companies Inc. Grows Stock Holdings in Bioventus Inc. $BVS - Defense World
Buy Signal: Why Bioventus Inc stock is favored by top institutionsQuarterly Portfolio Summary & Fast Entry Momentum Trade Alerts - BỘ NỘI VỤ
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Bioventus Inc. (BVS) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Dir Nohra Files To Sell 10,000 Of Bioventus Inc [BVS] - TradingView
Is It Too Late To Consider Buying Bioventus Inc. (NASDAQ:BVS)? - Yahoo Finance
Will Bioventus Inc. stock reach Wall Street targetsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Will Bioventus Inc. stock see insider buyingWeekly Stock Report & Short-Term High Return Ideas - Newser
(BVS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Bioventus Reports Strong Q3 2025 Financial Performance - MSN
Bioventus: A New Start (NASDAQ:BVS) - Seeking Alpha
How Bioventus Inc. stock performs in weak economy2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly - 富途牛牛
Bioventus (NYSE:BVS) Trading Down 3.9%Here's What Happened - MarketBeat
Bioventus, Inc. Reports Strong Q3 Earnings Growth - MSN
Segall Bryant & Hamill LLC Purchases 232,302 Shares of Bioventus Inc. $BVS - MarketBeat
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
[Form 3] Bioventus Inc. Initial Statement of Beneficial Ownership - Stock Titan
Bioventus (Nasdaq: BVS) to present at Piper Sandler 37th Healthcare Conference webcast - Stock Titan
Bioventus (NYSE:BVS) Shares Up 9.9%Time to Buy? - MarketBeat
Bioventus Appoints Ajay Dhankhar as New Director - MSN
Is Bioventus Inc. stock affected by interest rate hikesRisk Management & Weekly Chart Analysis and Guides - newser.com
Why Bioventus Inc. stock appeals to analystsJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Is Bioventus Inc. stock attractive for income investorsMarket Trend Review & Risk Adjusted Buy and Sell Alerts - newser.com
Bioventus Inc. stock prediction for this weekDollar Strength & High Conviction Investment Ideas - newser.com
Smart tools for monitoring Bioventus Inc.’s price actionEarnings Beat & Technical Pattern Alert System - newser.com
Can Bioventus Inc. rally from current levelsJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Bioventus Inc. (BVS) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Bioventus appoints Ajay Dhankhar to board as Class II director By Investing.com - Investing.com Australia
Bioventus appoints Ajay Dhankhar to board as Class II director - Investing.com
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors - TradingView
Bioventus Inc. Appoints Ajay Dhankhar to the Board as Class II Director, Effective November 14, 2025 - MarketScreener
[8-K] Bioventus Inc. Reports Material Event | BVS SEC FilingForm 8-K - Stock Titan
Campbell & CO Investment Adviser LLC Makes New Investment in Bioventus Inc. $BVS - MarketBeat
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):